Mora v. Secretary of Health and Human Services

122 Fed. Cl. 199, 2015 WL 4455027
United States Court of Federal Claims·Decided July 20, 2015·No. 13-421V·Published·Cited by 9 cases

Opinion

*200 Relief from Judgment; RCFC 60(b); Vaccine Rule 36(a)

OPINION AND ORDER

KAPLAN, Judge.

This case is before the Court on a motion for review of the February 27, 2015 decision of Special Master Laura Millman denying the petitioner’s motion seeking relief from judgment pursuant to Rule 60(b) of the Rules of the Court of Federal Claims (“RCFC”). For the reasons set forth below, the Court concludes that the Special Master’s decision is neither arbitrary, capricious, an abuse of discretion, nor contrary to law. 42 U.S.C. § 300aa-12(e)(2)(B). Accordingly, the motion for review must be DENIED.

BACKGROUND

I. The Original Petition and Its Voluntary Dismissal

This case arose out of a petition for compensation under the National Childhood Vaccine Injury Act, 42 U.S.C. §§ 300aa-l to 300aa-34 (2012) 1 that Lorena Mora, acting as guardian ad litem for her daughter, G.G.M., filed on June 25, 2013. According to the petition, G.G.M. was born in 2010. Pet. Vaccine Compensation ¶ 1, ECF No. 1. Petitioner states that the pregnancy and delivery were normal, without complications for either mother or child. Id. at ¶ 2. Prior to the facts given rise to this case, petitioner alleges, G.G.M. was in good health and was not diagnosed with any medical conditions. Id. at ¶ 4; Mot. for -Review at 3, Mar. 26, 2015, ECF No. 34.

When G.G.M. was two years old, Mrs. Mora, concerned about a rash on G.G.M.’s right leg that had been there for three days, took her to a healthcare provider. Special Master’s Order at 1, August 23, 2013, ECF No. 6 [hereinafter “SM Order”]. The provider diagnosed G.G.M. with dermatitis. Id. During the visit, G.G.M. received the influenza (“flu”) vaccine. Id. She had previously received a flu vaccine on October 26, 2011. Id. Two days after receiving the second flu vaccine, G.G.M. complained of abdominal pain, cried in pain, was unable to walk, and had not urinated since the previous night. SM Order at 1; Pet. ¶ 5. Mrs. Mora drove G.G.M. to the emergency room. Mot. for Review at 3. The doctor found that G.G.M. had sensory change and focal weakness, decreased tone in her lower extremities, and decreased deep tendon reflexes. SM Order at 1. She had no response to painful stimuli up to her abdomen. Id. at 1-2. The doctor narrowed down a possible diagnosis to botulism, transverse myelitis, or Guillain-Barré Syndrome. Id. G.G.M. was then transferred to the Kaiser Hospital where she was hospitalized from September 7, 2012 to October 6, 2012 and diagnosed with transverse myelitis caused by the flu vaccine. Id. at 2.

Petitioner states that G.G.M. is now completely paraplegic. Mot. for Review at 3. She further states that G.G.M. is “unable to ambulate and maneuvers around in a wheelchair” and that she “has a permanent catheter and has to be changed every three to four hours.” Id. In addition, petitioner asserts that as she “continues to grow toward adulthood, the life care planner estimated] that G.G.M. will need in-home health care, an extensive number of various orthopedic and urologie surgeries, and assorted medication due to her medical conditions resulting from her transverse myelitis.” Id.

After the petition for compensation was filed, petitioner made a settlement demand on March 11, 2014 to which the government made a counteroffer on July 11, 2014. Special Master’s Decision at 2, July 21, 2014, ECF No. 17. After reviewing the government’s counteroffer, petitioner requested a status conference with the Special Master and the government. Id. During the status conference, which was held on July 21, 2014, petitioner’s counsel reported that petitioner had “decided that she could receive more compensation in civil court against the vaccine administrator and manufacturer because *201 of the inapplicability of the collateral source rule in the Vaccine Program and the $250,000.00 cap for pain and suffering under the Vaccine Act.” Id. 2

Under the Vaccine Act, “[n]o person may bring a civil action for damages ... unless a petition has been filed ... for compensation under the Program ... and the United States Court of Federal Claims has issued a judgment under [42 U.S.C. § 300aa-12] ... and such person elects under [42 U.S.C. § 300aa-21(a) ] to file such an action.” 42 U.S.C. § 300aa-ll(a)(2)(A). Accordingly, in order to secure the necessary judgment, petitioner moved to dismiss her vaccine case. Mot. for Review at 3. The Special Master granted the motion to dismiss on June 11, 2014 without making any findings of fact or conclusions of law as to the merits of the petition for compensation. Special Master’s Decision at 2.

On August 11, 2014, the parties filed a joint notice of their intent not to seek review of the Special Master’s decision dismissing the case. Joint Notice of Decision Not to Seek Review at 1, ECF No. 19. The Clerk of the Court entered judgment on August 29, 2014, ECF No. 20, and petitioner filed a Notice of Election to File a Civil Action on September 26, 2014. ECF No. 22.

II. Petitioner’s Civil Action

On October 14, 2014, the petitioner filed a suit in the Los Angeles Superior Court alleging causes of action for strict products liability for manufacturing defect, design defect, and failure to warn against Sanofi Pasteur, Inc. (“Sanofi”), the manufacturer of the flu vaccine administered to G.G.M., and unnamed defendants, Does 1 through 100. Mot. for Review at 4; Attach, to Notice of Removal ¶¶ 21-57, G.M. v. Sanofi Pasteur, Inc., No. 2:14-09549 (C.D. Cal. Dee. 16, 2014). On December 4, 2014, petitioner demanded arbitration with Kaiser Permanente for medical malpractice and lack of informed consent based on the alleged failure of G.G.M.’s pediatrician and nurse to provide the Vaccine Administration Sheet to petitioner prior to administering G.G.M.’s vaccination on September 5, 2012. Mot. for Review at 4.

On December 16; 2014, Sanofi filed a Notice of Removal to federal court based on diversity jurisdiction and the United States Supreme Court’s decision in Bruesewitz v. Wyeth L.L.C., 562 U.S. 223, 131 S.Ct. 1068, 179 L.Ed.2d 1 (2011). Notice of Removal at 2, G.M. v. Sanofi Pasteur, Inc., No. 2:14-09549 (C.D. Cal. Dec. 16,2014). In that case, the Supreme Court, interpreting 42 U.S.C. § 300aa-22(b)(1), 3

Free access — add to your briefcase to read the full text and ask questions with AI

Mora v. Secretary of Health and Human Services, 122 Fed. Cl. 199, 2015 WL 4455027 (uscfc 2015).

122 Fed. Cl. 199 (Mora v. Secretary of Health and Human Services) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related